Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)

Wheaton Precious Metals (NYSEWPM) (TSX: WPM) announced ReThink Milling Inc. as the winner of its inaugural Future of Mining Challenge, awarding the company $1 million for its Conjugate Anvil Hammer Mill (CAHM) and MonoRoll technologies. These innovations aim to enhance milling efficiency while significantly reducing energy consumption, greenhouse gas emissions, and operating costs. Wheaton launched the challenge in September 2024 to identify scalable solutions for improving sustainability in mining. CEO Randy Smallwood emphasized the importance of industry support in advancing new technologies, while ReThink Milling expressed excitement for the next phase of commercialization.

Tonix shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results.

Tonix Pharmaceuticals (NASDAQTNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cash equivalents as of Dec. 31. Net cash used in operations declined to $60.9 million from $102 million the prior year, while net revenue rose to $10.1 million from $7.8 million. The company recorded a net operating loss of $126.6 million, including $59 million in non-cash impairment charges. Tonix repaid its mortgage on Feb. 3, 2025, becoming debt-free, and expects its cash resources and recent fundraising to support operations into early 2026, covering the FDA’s Aug. 15, 2025, PDUFA decision date for TNX-102 SL in fibromyalgia management.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

Tonix Pharmaceuticals (NASDAQTNXP) announced positive topline results from its Phase 1 trial of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy participants. The study demonstrated TNX-1500 was well tolerated, with no serious adverse events or thromboembolic complications, and effectively blocked immune responses at higher doses. The pharmacokinetics support monthly dosing at 10 mg/kg or above, positioning the drug as a potential best-in-class therapy for preventing organ transplant rejection and treating autoimmune diseases. Tonix plans to discuss these findings with the FDA in preparation for a Phase 2 study in kidney transplant recipients.

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Tonix Pharmaceuticals (NASDAQTNXP) announced that its President and CEO, Seth Lederman, M.D., will present at the BIO CEO & Investor Conference on Feb. 10, 2025, at 1:45 p.m. ET in New York City. The company, which develops biopharmaceutical products, invites investors to arrange meetings with management through the conference’s registration platform.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.

Let's have a look at the gap up and gap down stocks in today's session.

Tonix Pharmaceuticals (NASDAQTNXP) announced the promotion of Siobhan Fogarty to chief technical officer. Fogarty, who joined Tonix in 2016, previously served as executive vice president of product development and has over 25 years of experience in pharmaceutical and biotech product development, manufacturing and quality. Her promotion comes as the company prepares for the U.S. Food and Drug Administration’s Aug. 15, 2025, decision on TNX-102 SL, a non-opioid treatment for fibromyalgia. Fogarty’s expertise spans small molecules, biologics and live-virus vaccines, having held leadership roles at Elan Corporation, GlaxoSmithKline, Fuisz Technologies and Biovail Corporation.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Tonix Pharmaceuticals (NASDAQTNXP) will implement a 1-for-100 reverse stock split, effective at market open on Feb. 5, 2025, to meet NASDAQ’s $1.00 minimum bid price requirement. The company’s stock will continue trading under the symbol “TNXP” with a new CUSIP number. The split applies to outstanding common shares, warrants, and stock options but does not reduce authorized shares. Fractional shares will be rounded up to the nearest whole share. VStock Transfer LLC will manage the exchange process for shareholders

Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.